Literature DB >> 1397838

p53: the ultimate tumor suppressor gene?

M Oren1.   

Abstract

Alterations in the gene encoding the cellular p53 protein are perhaps the most frequent type of genetic lesions in human cancer. At the heart of these alterations is the abrogation of the tumor suppressor activity of the normal p53. In many cases this is achieved through point mutations in p53, which often result in pronounced conformational changes. Such mutant polypeptides, which tend to accumulate to high levels in cancer cells, are believed to exert a dominant negative effect over coexpressed normal p53. Extensive research on p53, especially in the course of the last 3 years, has already provided much insight into the biological and biochemical mechanisms that underlie its capacity to act as a potent tumor suppressor. There are now many indications that p53 may play a central role in the control of cell proliferation, cell survival, and differentiation. Nevertheless, despite the purported importance of p53 for such crucial processes, mice can develop apparently without any defect in the total absence of p53. This raises the possibility that p53 may become critically limiting only when normal growth control is lost.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397838     DOI: 10.1096/fasebj.6.13.1397838

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  55 in total

Review 1.  Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Authors:  M Merup
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

2.  Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines.

Authors:  J Lotem; M Peled-Kamar; Y Groner; L Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

3.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation.

Authors:  Y Qi; J K Wang; M McMillian; D M Chikaraishi
Journal:  J Neurosci       Date:  1997-02-15       Impact factor: 6.167

5.  Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.

Authors:  Gad Asher; Joseph Lotem; Leo Sachs; Chaim Kahana; Yosef Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

6.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.

Authors:  H Kim; J Jen; B Vogelstein; S R Hamilton
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

7.  PAK1, a gene that can regulate p53 activity in yeast.

Authors:  S Thiagalingam; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

8.  Immunihistochemical detection of Bcl-2 in AIDS-associated and classical Kaposi's sarcoma.

Authors:  C B Morris; R Gendelman; A J Marrogi; M Lu; J M Lockyer; W Alperin-Lea; B Ensoli
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

9.  Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice.

Authors:  G Li; D L Mitchell; V C Ho; J C Reed; V A Tron
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

10.  Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53.

Authors:  S J Ullrich; K Sakaguchi; S P Lees-Miller; M Fiscella; W E Mercer; C W Anderson; E Appella
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.